Source - LSE Regulatory
RNS Number : 8001I
Creo Medical Group PLC
16 August 2021
 

THIS ANNOUNCEMENT, INLCUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

LEI: 213800H188ZDCWWXFA21

 

 

16 August 2021

 

Creo Medical Group plc

("Creo" or the "Company")

 

Launch of Open Offer, Posting of Circular

and

Notice of General Meeting

 

 

The Company is pleased to announce that, further to the announcement made on 12 August 2021 (RNS No: 5145I ) regarding the Fundraising (the "Launch Announcement"), it is proposing to raise up to approximately £5.07 million (before expenses) through an Open Offer pursuant to which Qualifying Shareholders will have an opportunity to subscribe for an aggregate of 2,775,896 Open Offer Shares at an Offer Price of 182.5 pence per Open Offer Share.

 

Pursuant to the Open Offer, Qualifying Shareholders will be given the opportunity to subscribe for:

 

1 Open Offer Share for every 58 Existing Ordinary Shares

 

held by Qualifying Shareholders at the Record Date and so on in proportion for any other number of Existing Shares then held.

 

Any Open Offer Shares not subscribed for by Qualifying Shareholders will be available to Qualifying Shareholders under the Excess Application Facility and as such, Qualifying Shareholders seeking to limit their dilution from the Placing can also request additional Open Offer Shares ("Excess Shares") under the Excess Application Facility. The Open Offer is not being underwritten. 

 

The Open Offer is conditional upon, among other things (i) the Resolutions being duly passed by Shareholders at the General Meeting and (ii) Admission having become effective at or before 8.00 a.m. on 7 September 2021 (or such later time and/or date as Cenkos may agree with the Company not being later than 8.00 a.m. on 14 September 2021).

 

Posting of Circular 

The Company also confirms that a circular, which contains further details regarding the Open Offer and a notice convening the General Meeting (the "Circular"), has been posted today to Qualifying Shareholders, along with the Application Form (where applicable). The Circular will also be made available on the Company's website: www.creomedical/investors.

 

Notice of General Meeting

The General Meeting has been convened for 6 September 2021 at 10 a.m. at the offices of Osborne Clarke LLP, 2 Temple Back East, Temple Quay, Bristol BS1 6EG.

 

Capitalised terms used in this announcement have the meanings given to them in the Circular unless the context provides otherwise.

 

 

Creo Medical Group plc

www.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005

 

 

Cenkos Securities plc

+44 (0)20 7397 8900

Stephen Keys / Camilla Hume (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Lianne Cawthorne 

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 

       

 

Expected Timetable for the Fundraising

 

 

Announcement of the Fundraising

2021

12 August

 

Record Date for entitlement under the Open Offer

12 August

 

Announcement of the results of the Placing

13 August

 

Publication of the Circular, Proxy Form and, to Qualifying Non-Crest Shareholders, the Application Form

16 August

 

 

Ex-entitlement date of the Open Offer

16 August

 

Open Offer Entitlements and Excess Open Offer Entitlements credited to stock accounts in CREST of Qualifying CREST Shareholders

17 August

 

 

Latest recommended time and date for requested withdrawal of Basic Open Offer Entitlements from CREST

4.30 p.m. on 27 August

 

 

Latest time and date for depositing Open Offer Entitlements in CREST

3.00 p.m. on 31 August

 

Latest time and date for splitting of Application Forms under the Open Offer

3.00 p.m. on 1 September

 

Latest time and date for receipt of Forms of Proxy and CREST voting instructions

10.00 a.m. on 2 September

 

Latest time and date for receipt of Application Forms and payment in full under the Open Offer and settlement of relevant CREST instructions (as appropriate)

11.00 a.m. on 3 September

 

 

General Meeting

10.00 a.m. on 6 September

 

Results of the General Meeting and the Open Offer announced

6 September

 

Admission of the New Ordinary Shares to trading on AIM and commencement of dealings

8.00 a.m. on 7 September

 

 

Where applicable, expected date for CREST accounts to be credited in respect of New Ordinary Shares in uncertificated form

7 September

 

 

Where applicable, expected date for despatch of definitive share certificates for New Ordinary Shares in certificated form

21 September

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURGPUUWRUPGGCQ
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Creo Medical Group PLC (CREO)

-0.50p (-1.44%)
delayed 17:08PM